ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

A lawsuit against the genomics company "imposes top-down restrictions" rather than "establishing clear rules" or "letting ...

The National Weather Service issued the heat advisory earlier this week, with temperatures in central Alaska climbing to the ...

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Well, 23andMe has gone from being valued at $6 billion to bankruptcy with its assets being won last month by biotech firm Regeneron during a bankruptcy auction. The winning bid, $256 million. But late ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Anne Wojcicki, founder of 23andMe, has successfully repurchased the genetic testing firm out of bankruptcy through her ...

Regeneron Pharmaceuticals said last month it aimed to buy the company for $256 million. Regeneron said it would comply with 23andMe’s privacy policies and applicable law.

The state of Texas lost its bid for a temporary restraining order to halt the proposed sale of 23andMe’s genetic data bank, ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...